Literature DB >> 14704031

The role of the MLL gene in infant leukemia.

Mariko Eguchi1, Minenori Eguchi-Ishimae, Mel Greaves.   

Abstract

The MLL gene is a major player in leukemia, particularly in infant leukemia and in secondary, therapy-related acute leukemia. The normal MLL gene plays a key role in developmental regulation of gene expression (including HOX genes), and in leukemia this function is subverted by breakage, recombination, and chimeric fusion with one of 40 or more alternative partner genes. In infant leukemias, the chromosome translocations involving MLL arise during fetal hematopoiesis, possibly in a primitive lymphomyeloid stem cell. In general, these leukemias have a very poor prognosis. The malignancy of these leukemias is all the more dramatic considering their very short preclinical natural history or latency. These data raise fundamental issues of how such divergent MLL chimeric genes transform cells, why they so rapidly evolve to a malignant status, and what alternative or novel therapeutic strategies might be considered. We review here progress in tackling these questions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14704031     DOI: 10.1007/bf02983811

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  125 in total

1.  A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.

Authors:  J F DiMartino; T Miller; P M Ayton; T Landewe; J L Hess; M L Cleary; A Shilatifard
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.

Authors:  Chi Wai So; Min Lin; Paul M Ayton; Everett H Chen; Michael L Cleary
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

3.  Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.

Authors:  C Lavau; R T Luo; C Du; M J Thirman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice.

Authors:  Chi Wai So; Holger Karsunky; Emmanuelle Passegué; Antonio Cozzio; Irving L Weissman; Michael L Cleary
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

5.  Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.

Authors:  H Kawasaki; K Isoyama; M Eguchi; S Hibi; N Kinukawa; Y Kosaka; T Oda; M Oda; S Nishimura; M Imaizumi; T Okamura; T Hongo; H Okawa; S Mizutani; Y Hayashi; I Tsukimoto; N Kamada; E Ishii
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

6.  Absence of p53 permits propagation of mutant cells following genotoxic damage.

Authors:  S D Griffiths; A R Clarke; L E Healy; G Ross; A M Ford; M L Hooper; A H Wyllie; M Greaves
Journal:  Oncogene       Date:  1997-02-06       Impact factor: 9.867

7.  Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.

Authors:  C Lavau; C Du; M Thirman; N Zeleznik-Le
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

Review 8.  Leukemia in twins: lessons in natural history.

Authors:  Mel F Greaves; Ana Teresa Maia; Joseph L Wiemels; Anthony M Ford
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

9.  Rapid intraclonal switch of lineage dominance in congenital leukaemia with a MLL gene rearrangement.

Authors:  S A Ridge; M E Cabrera; A M Ford; S Tapia; C Risueño; S Labra; F Barriga; M F Greaves
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

10.  Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties.

Authors:  Akihiko Yokoyama; Issay Kitabayashi; Paul M Ayton; Michael L Cleary; Misao Ohki
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

View more
  14 in total

1.  Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.

Authors:  Chenxi Shen; Stephanie Y Jo; Chenzhong Liao; Jay L Hess; Zaneta Nikolovska-Coleska
Journal:  J Biol Chem       Date:  2013-09-01       Impact factor: 5.157

2.  MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Authors:  Corina Buechele; Erin H Breese; Dominik Schneidawind; Chiou-Hong Lin; Johan Jeong; Jesus Duque-Afonso; Stephen H K Wong; Kevin S Smith; Robert S Negrin; Matthew Porteus; Michael L Cleary
Journal:  Blood       Date:  2015-08-26       Impact factor: 22.113

Review 3.  Roles of a trithorax group gene, MLL, in hematopoiesis.

Authors:  Ryoichi Ono; Tetsuya Nosaka; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

Review 4.  Chromosomal translocations involving the MLL gene: molecular mechanisms.

Authors:  Peter D Aplan
Journal:  DNA Repair (Amst)       Date:  2006-06-21

5.  Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.

Authors:  Jolanta Grembecka; Amalia M Belcher; Thomas Hartley; Tomasz Cierpicki
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

6.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Authors:  Jonathan J Keats; Christopher A Maxwell; Brian J Taylor; Michael J Hendzel; Marta Chesi; P Leif Bergsagel; Loree M Larratt; Michael J Mant; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

Review 7.  Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects.

Authors:  David P Harper; Peter D Aplan
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 8.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

9.  AF17 competes with AF9 for binding to Dot1a to up-regulate transcription of epithelial Na+ channel alpha.

Authors:  Mary Rose Reisenauer; Marc Anderson; Le Huang; Zhijing Zhang; Qiaoling Zhou; Bruce C Kone; Andrew P Morris; Gene D Lesage; Stuart E Dryer; Wenzheng Zhang
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 10.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.